Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unmet LDL-C target in very high-risk cardiovascular patients after stepwise lipid-lowering therapy
NL-OMON21157Phase 4Active, not recruiting
- Sponsor
- WorldCare
- Start
- Jan 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of alirocumab, ezetimibe, atorvastatin and rosuvastatin in hypercholesterolemia, combined dyslipidaemia and hyperlipidemia (3 arms), sponsored by WorldCare. Primary endpoint: Proportion of patients with LDL-C >1.8 mmol/L during stepwise lipid-lowering therapy. Started Jan 2019; status: active, not recruiting.
02
Drugs
alirocumabezetimibeatorvastatinrosuvastatin
03
Conditions
hypercholesterolemiacombined dyslipidaemiahyperlipidemia
Beyond the preview
Go deeper on NL-OMON21157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21157.